Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Ransdell Pierson  |  March 18, 2016

(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…

Psoriasis Drug Succeeds in Mid-Stage Study

Reuters Staff  |  March 17, 2016

(Reuters)—Drug developer Vitae Pharmaceuticals Inc. said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70% in after-hours trading. Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction…

Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants

Jessica Dye  |  March 17, 2016

NEW YORK (Reuters)—Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay a total of about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants. Following a two-month trial, jurors found that the Pinnacle hips were defectively designed, and that the…

Smartphones Not So Smart with Urgent Medical Questions

Lisa Rapaport  |  March 16, 2016

(Reuters Health)—Smartphones are the first thing many people turn to with questions about their health. But when it comes to urgent queries about issues like suicide, rape and heart attack, phones can be pretty bad at offering good medical advice, a new study suggests. Researchers tested four commonly used conversation agents that respond to users’…

Women Lag Men as Lead Authors in Top Medical Journals

Lisa Rapaport  |  March 11, 2016

(Reuters Health)—Women are more apt to be lead authors of research in major medical journals today than they were a generation ago, but they still lag significantly behind men, a recent study suggests. The gender gap matters because lead authors make key decisions on what topics to research, who to include in studies, which outcomes…

U.S. Health Agency Estimates 2015 Prescription Drug Spending Rose to $457 Billion

Reuters Staff  |  March 10, 2016

NEW YORK (Reuters)—Spending on prescription drugs is projected to have risen to $457 billion in 2015 and will likely continue to grow as a percentage of overall healthcare spending, a U.S. government health agency said on Tuesday. That is an increase of about 8% from 2014’s prescription drug spending, which is also an estimated figure,…

Health Apps Often Lack Privacy Policies & Share Our Data

Lisa Rapaport  |  March 10, 2016

(Reuters Health)—Just because a health app has a privacy policy doesn’t mean the data will remain private, an analysis of mobile tools for diabetes suggests. In fact, privacy policies appear rare, and when they do exist, most state that user data will be collected and half warn that medical information will be shared with third…

Routine Osteoporosis Screening in Men Proves Cost-Effective

Shannon Aymes  |  March 8, 2016

NEW YORK (Reuters Health)—Routine osteoporosis screening in men is a good value and effective based on a cost-effectiveness model, researchers say. “Osteoporosis is not just a disease for women. Osteoporosis affects many men (approximately 2 million in the U.S.), with significant morbidity, mortality, and costs that are projected to rise with the aging of the…

Doctor Quality Ratings May Be Influenced By Setting

Madeline Kennedy  |  March 8, 2016

(Reuters Health)—Patients give the same doctors different ratings depending on where their visit took place, according to a small U.S. study. Although doctors might act differently in an emergency department compared with a calmer office setting, researchers say the results also suggest that ratings are not a completely reliable measure of the quality of care…

Europe Launches New Fast Approval Scheme for Promising Drugs

Reuters Staff  |  March 7, 2016

LONDON (Reuters)—European regulators launched a new scheme on Monday to speed the approval of promising new drugs that address unmet medical needs by offering enhanced support to medicine developers as they work on clinical trials. The European Medicines Agency‘s (EMA) initiative called PRIME, which stands for PRIority MEdicines, is the latest example of regulators on…

  • « Previous Page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • 71
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences